Additionally, we show in breast cancer cells that abemaciclib stabilizes primed CDK4-cyclin D complex and displaces p21, not observed in CDK6-cyclin D models, resulting in altered sensitivity in breast cancer models with greater CDK6 expression. Here, CDK6 is linked to breast carcinoma.